4/11
08:55 am
pcrx
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend [Yahoo! Finance]
Medium
Report
Pacira BioSciences (NASDAQ:PCRX) stock falls 4.1% in past week as three-year earnings and shareholder returns continue downward trend [Yahoo! Finance]
4/9
08:09 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
4/2
08:00 am
pcrx
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
Low
Report
Pacira BioSciences to Participate in Fireside Chat at the 23rd Annual Needham Virtual Healthcare Conference
3/14
09:40 am
pcrx
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag [Yahoo! Finance]
Low
Report
Pacira's (PCRX) Knee Osteoarthritis Drug Gets FDA's RMAT Tag [Yahoo! Finance]
3/13
07:16 am
pcrx
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee [Yahoo! Finance]
Medium
Report
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee [Yahoo! Finance]
3/13
07:00 am
pcrx
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
Medium
Report
Pacira BioSciences Announces PCRX-201 Granted Regenerative Medicine Advance Therapy (RMAT) Designation for the Treatment of Osteoarthritis of the Knee
3/9
12:17 am
pcrx
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) [Yahoo! Finance]
Low
Report
Director Gary Pace Sells 119,323 Shares of Pacira BioSciences Inc (PCRX) [Yahoo! Finance]
3/7
08:02 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $45.00 price target on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "overweight" rating re-affirmed by analysts at JPMorgan Chase & Co.. They now have a $45.00 price target on the stock.
3/6
08:00 am
pcrx
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
Low
Report
Pacira BioSciences to Participate in Fireside Chat at the Barclays 26th Annual Global Healthcare Conference
3/4
08:06 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $57.00 price target on the stock.
3/1
06:20 pm
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) was upgraded by analysts at TheStreet from a "d+" rating to a "c" rating.
3/1
11:15 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $45.00. They now have an "outperform" rating on the stock.
Low
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its price target lowered by analysts at Royal Bank of Canada from $53.00 to $45.00. They now have an "outperform" rating on the stock.
3/1
08:58 am
pcrx
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
Medium
Report
Pacira BioSciences, Inc. (NASDAQ:PCRX) Q4 2023 Earnings Call Transcript [Yahoo! Finance]
3/1
08:19 am
pcrx
Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
Medium
Report
Pacira BioSciences Full Year 2023 Earnings: EPS Beats Expectations [Yahoo! Finance]
3/1
08:15 am
pcrx
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
Medium
Report
Pacira BioSciences, Inc. (NASDAQ: PCRX) had its "buy" rating re-affirmed by analysts at Needham & Company LLC. They now have a $45.00 price target on the stock.
3/1
07:59 am
pcrx
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues [Yahoo! Finance]
Medium
Report
Pacira (PCRX) Q4 Earnings Match, Exparel Sales Drive Revenues [Yahoo! Finance]
2/29
11:43 am
pcrx
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings [Yahoo! Finance]
Low
Report
Here's What Key Metrics Tell Us About Pacira (PCRX) Q4 Earnings [Yahoo! Finance]
2/29
08:40 am
pcrx
Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023 [Yahoo! Finance]
Low
Report
Pacira BioSciences Inc (PCRX) Reports Record Revenues and Robust Earnings for Full-Year 2023 [Yahoo! Finance]
2/29
08:14 am
pcrx
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
Low
Report
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results [Yahoo! Finance]
2/29
08:00 am
pcrx
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
Low
Report
Pacira BioSciences Reports Fourth Quarter and Full-Year 2023 Financial Results
2/26
11:03 am
pcrx
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics [Yahoo! Finance]
Low
Report
Countdown to Pacira (PCRX) Q4 Earnings: Wall Street Forecasts for Key Metrics [Yahoo! Finance]
2/22
08:00 am
pcrx
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
Low
Report
Pacira to Report 2023 Financial Results on Thursday February 29, 2024
2/17
01:58 am
pcrx
Heron Therapeutics Is Out Of Survival Mode [Seeking Alpha]
Low
Report
Heron Therapeutics Is Out Of Survival Mode [Seeking Alpha]
2/15
08:52 am
pcrx
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy [Yahoo! Finance]
Low
Report
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy [Yahoo! Finance]
2/15
08:36 am
pcrx
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy
Low
Report
Pacira Announces Publication of Pivotal Study of EXPAREL as a Sciatic Nerve Block in the Popliteal Fossa for Patients After Bunionectomy